Provided by Tiger Trade Technology Pte. Ltd.

VanEck Healthcare TruSector ETF

29.53
+0.20350.69%
Volume:222
Turnover:6.57K
Market Cap:590.60K
PE:- -
High:29.53
Open:29.53
Low:29.53
Close:29.33
52wk High:30.68
52wk Low:24.78
Shares:20.00K
Float Shares:20.00K
Volume Ratio:0.93
T/O Rate:1.11%
Dividend:0.21
Dividend Rate:0.73%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Eli Lilly and Co Stock (LLY) Moved Up by 3.94% on Oct 7: Facts Behind the Movement

TradingKey
·
Oct 08

Amgen Inc Stock (AMGN) Moved Up by 3.06% on Oct 7: A Full Analysis

TradingKey
·
Oct 08

S&P 500 Top and Bottom Performing Stocks at About 12:00 P.m. EDT

Reuters
·
Oct 08

Pharma Lobby Sues Trump Administration over Medicare Drug Price Cuts

Reuters
·
Oct 07

Eli Lilly is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Oct 07

What Eli Lilly Stock's First Line Jaypirca Approval Means For Shareholders

Simply Wall St.
·
Oct 07

Halozyme Therapeutics Shares up 2% After Court Win Against Merck to Block Subcutaneous Keytruda in Select Markets

THOMSON REUTERS
·
Oct 07

Micro-Cap Stock Veraxa Biotech is Down 96% This Year. Can Next-Gen Drug Testing Save It?

Dow Jones
·
Oct 07

Morgan Stanley Adjusts Price Target on Merck to $177 From $179

MT Newswires Live
·
Oct 07

AbbVie’s telisotuzumab adizutecan gets two FDA Breakthrough Therapy Designations

TIPRANKS
·
Oct 07

Tempus AI announces multi-year collaboration with Moderna, Merck

TIPRANKS
·
Oct 07

Halozyme announces Dutch court of the Hague found Merck infringed patents

TIPRANKS
·
Oct 07

AbbVie Says FDA Grants Breakthrough Therapy Status for ABBV-400 in Metastatic Colorectal Cancer

Reuters
·
Oct 07

Tempus Expands Multi-Year Collaboration with Moderna, Merck on V940 Melanoma Vaccine Commercialization Support

Reuters
·
Oct 07

Abbvie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations from the U.S. FDA for Crc and Nsclc

THOMSON REUTERS
·
Oct 07

Halozyme Therapeutics - Iv Version of Keytruda Remains Available and not Covered by Halozyme's Patent or Court Injunction

THOMSON REUTERS
·
Oct 07

Halozyme Therapeutics - Court Rejects Merck's Arguments That Ep622 Patent is Invalid

THOMSON REUTERS
·
Oct 07

Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda Sc in Multiple European Markets

THOMSON REUTERS
·
Oct 07

Halozyme Therapeutics - Court Orders Msd BV to Stop Keytruda Sc Manufacture and Sale in Eight European Countries

THOMSON REUTERS
·
Oct 07

Halozyme Therapeutics - Injunction Forbids Msd from Facilitating Infringement by Affiliates

THOMSON REUTERS
·
Oct 07